Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy.

PURPOSE To investigate the relationship between insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the vitreous fluid of diabetic patients with proliferative diabetic retinopathy (PDR). DESIGN Observational case-control study. METHODS In a prospective study, 37 consecutive diabetic patients with PDR (14 type I and 23 type II diabetes mellitus) in whom a vitrectomy was performed were compared with 21 nondiabetic patients with other conditions requiring vitrectomy (control group). Free IGF-I and VEGF were measured by ELISA. RESULTS Vitreal levels of both free IGF-1 and VEGF were higher in diabetic patients with PDR than in control subjects (P <.01, and P <.0001, respectively). After adjusting for total intravitreous protein concentration, VEGF (ng/mg of proteins) remained significantly higher in diabetic patients with PDR than in the control group (P <.0001), whereas free IGF-I (ng/mg of proteins) was lower in diabetic patients than in control subjects (P <.0001). The vitreous concentrations of VEGF were higher in patients with active PDR than in patients with quiescent PDR (P <.005), whereas vitreous free IGF-I was not related to PDR activity. Finally, we did not observe a correlation between the vitreal levels of free IGF-I and VEGF. CONCLUSIONS We conclude that free IGF-I and VEGF are both increased, but not related, within the vitreous fluid of diabetic patients with PDR. In addition, our results support the current concept that VEGF is directly involved in the pathogenesis of PDR, whereas the precise role of free IGF-I remains to be established.

[1]  M. Shibuya,et al.  Increase of vascular endothelial growth factor mRNA expression by 1,25‐dihydroxyvitamin D3 in human osteoblast‐like cells , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  E S Gragoudas,et al.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.

[3]  D. Donner,et al.  Induction of Vascular Endothelial Growth Factor by Insulin-like Growth Factor 1 in Colorectal Carcinoma* , 1996, The Journal of Biological Chemistry.

[4]  M. Boulton,et al.  Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management , 1997, The British journal of ophthalmology.

[5]  R. Knott.  Insulin-like growth factor type 1—friend or foe? , 1998, The British journal of ophthalmology.

[6]  Joan W. Miller,et al.  Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. , 1994, The American journal of pathology.

[7]  V. Fairbanks,et al.  Methods for measuring plasma hemoglobin in micromolar concentration compared. , 1992, Clinical chemistry.

[8]  H. Esumi,et al.  Regulation of vascular endothelial growth factor expression by insulin‐like growth factor‐I in endometrial adenocarcinoma cells , 2000, International journal of cancer.

[9]  M. Harboe,et al.  A method for determination of hemoglobin in plasma by near-ultraviolet spectrophotometry. , 1959, Scandinavian journal of clinical and laboratory investigation.

[10]  G F Vrensen,et al.  Endothelial cell hypertrophy induced by vascular endothelial growth factor in the retina: new insights into the pathogenesis of capillary nonperfusion. , 2001, Archives of ophthalmology.

[11]  E. Chantelau,et al.  Evidence that upregulation of serum IGF-1 concentration can trigger acceleration of diabetic retinopathy , 1998, The British journal of ophthalmology.

[12]  H. Freyberger,et al.  Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. , 1993, The Journal of clinical investigation.

[13]  R. Simó,et al.  Vitreous levels of vascular cell adhesion molecule and vascular endothelial growth factor in patients with proliferative diabetic retinopathy: a case-control study. , 2001, Diabetes care.

[14]  Circulating IGF‐I and its protective role in the pathogenesis of diabetic angiopathy , 2000, Clinical endocrinology.

[15]  Lois E. H. Smith,et al.  Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Lois E. H. Smith,et al.  Essential role of growth hormone in ischemia-induced retinal neovascularization. , 1997, Science.

[17]  R. Simó,et al.  Vitreous levels of IGF-I, IGF binding protein 1, and IGF binding protein 3 in proliferative diabetic retinopathy: a case-control study. , 2000, Diabetes care.

[18]  E. Kohner,et al.  Florid Diabetic Retinopathy and its Response to Treatment by Photocoagulation or Pituitary Ablation , 1976, Diabetes.

[19]  L. Maile,et al.  The role of cell surface attachment and proteolysis in the insulin-like growth factor (IGF)-independent effects of IGF-binding protein-3 on apoptosis in breast epithelial cells. , 1999, Endocrinology.

[20]  E S Gragoudas,et al.  Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. , 1996, Archives of ophthalmology.

[21]  A. Allers,et al.  Vitreous concentrations of TPA and plasminogen activator inhibitor are associated with VEGF in proliferative diabetic vitreoretinopathy. , 1999, Retina.

[22]  M. Grant,et al.  Insulin-Like Growth Factors in Vitreous: Studies in Control and Diabetic Subjects with Neovascularization , 1986, Diabetes.

[23]  D. Clemmons,et al.  Use of mutagenesis to probe IGF-binding protein structure/function relationships. , 2001, Endocrine reviews.

[24]  D. Roith.  Insulin-like growth factor. , 1999 .

[25]  Lois E. H. Smith,et al.  Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor , 1999, Nature Medicine.

[26]  R. D'Amato,et al.  Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I , 1997, Diabetes.

[27]  E. Kohner,et al.  A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. , 1989, Metabolism: clinical and experimental.

[28]  W. Lowe,et al.  Regulation of growth factor mRNA levels in the eyes of diabetic rats. , 1995, Metabolism: clinical and experimental.

[29]  R. Simó,et al.  Vitreous levels of vascular endothelial growth factor are not influenced by its serum concentrations in diabetic retinopathy , 1997, Diabetologia.

[30]  C. Patterson,et al.  Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I. , 1996, Endocrinology.

[31]  L. Aiello,et al.  Cyclic stretch and hypertension induce retinal expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2: potential mechanisms for exacerbation of diabetic retinopathy by hypertension. , 2001, Diabetes.

[32]  E. Guillet,et al.  Elevated γ-Aminobutyric Acid, Glutamate, and Vascular Endothelial Growth Factor Levels in the Vitreous of Patients With Proliferative Diabetic Retinopathy , 1997 .

[33]  M. Binoux,et al.  Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action. , 1997, Endocrinology.

[34]  C. Gerhardinger,et al.  IGF-I mRNA and signaling in the diabetic retina. , 2001, Diabetes.

[35]  T. Takamura,et al.  Plasma Levels of Vascular Endothelial Growth Factor in Patients with Acromegaly , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[36]  A. Flyvbjerg,et al.  Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. , 1998, Metabolism: clinical and experimental.

[37]  M. Binoux,et al.  A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. , 1996, Endocrinology.

[38]  R. Klein,et al.  Does Insulin-Like Growth Factor I Predict Incidence and Progression of Diabetic Retinopathy? , 1995, Diabetes.

[39]  Lois E. H. Smith,et al.  Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Tarnuzzer,et al.  Insulin-like growth factor: receptor and binding proteins in human retinal endothelial cell cultures of diabetic and non-diabetic origin. , 1998, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[41]  L. Aiello,et al.  Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  E. Kohner,et al.  Progression of Diabetic Retinopathy and Changes in Serum Insulin-Like Growth Factor I (IGF I) during Continuous Subcutaneous Insulin Infusion (CSII) , 1989, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[43]  T. Merimee.  A follow-up study of vascular disease in growth-hormone-deficient dwarfs with diabetes. , 1978, The New England journal of medicine.

[44]  L. Aiello,et al.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. , 1994, The New England journal of medicine.

[45]  V. Duance,et al.  Elevated levels of proteolytic enzymes in the aging human vitreous. , 2000, Investigative ophthalmology & visual science.

[46]  G. Lang,et al.  Growth factor combinations modulate human retinal pigment epithelial cell proliferation , 2000 .

[47]  L. Ellis,et al.  Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. , 1998, Cancer research.